Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

CeloNova unveils study results for new class of coronary stent

CeloNova BioSciences : 21 January, 2008  (New Product)
CeloNova BioSciences has revealed breakthrough results from the Atlanta study of the Catania Coronary Stent System with NanoThin Polyzene-F at the 20th Annual International Symposium on Endovascular Therapy (ISET).
Corrado Tamburino, MD, president of the Italian Society of Interventional Cardiology, chief of interventional cardiology at Ferrarotto Hospital and full professor of cardiology at the University of Catania is principal investigator for the Atlanta study.

Dr Tamburino noted, 'I perform many angioplasties in each single day, many, and I am totally impressed by the performance of this Stent in a very complex patient population. No thrombosis. Low binary restenosis. No MIs. This may be an answer to the problems we are facing with other Stent systems.'

The Catania Stent System with NanoThin Polyzene-F, dubbed ‘The CAT’ by cardiologists who have used the product, has completed CE Mark approval. Advantages include:

- Early and complete vessel healing, as early as 30 days.

- Patients can discontinue dual anti-platelet therapy after only one month.

- Protection from Stent thrombosis

- The Polyzene-F surface treatment is bacterial-resistant

'The FDA has cautioned physicians about a small but significant increased risk of Stent thrombosis for patients with drug-eluting stents. Now, Britain's National Institute for Health and Clinical Excellence is considering restrictions on DES because they are not cost-effective for most patients and because of uncertainties about safety. Polyzene-F seems to solicit a positive biological response that treats the Stent as accepted part of the vessel. As a result, 'The CAT' patients have excellent outcomes and can be free from the medical complications and financial burden associated with indefinite anti-platelet therapy,' stated Thomas A Gordy, president and chief executive officer.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   Â© 2012
Netgains Logo